Case Study
Advancing therapeutics for myeloma
Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement for more efficient and tolerable therapies.
Oncopeptides, a clinical stage company, has partnered with Recipharm's analytical chemistry team to help take a promising molecule from the discovery phase to clinical trials, with the end goal of commercial production. Download the full case study to read more about the project and Recipharm's development services.
